![\"\"](\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2026\/02\/CROI-page-banner.png\")
<\/p>\n<\/p>\n
Simon Collins, HIV i-Base<\/strong><\/p>\n This page lists all i-Base reports the recent CROI 2026 conference held in Denver from 22 to 25 February,<\/strong><\/p>\n All reports include hyperlinks to abstracts, poster and webcasts.<\/p>\n This page was ipdated on 24 April 2026 to include all reports from CROI 2026.<\/p>\n","protected":false},"excerpt":{"rendered":" Simon Collins, HIV i-Base This page lists all i-Base reports the recent CROI 2026 conference held in Denver from 22 to 25 February, All reports include hyperlinks to abstracts, poster and webcasts. CROI 2026: investigational HIV combinations \u2013 daily, weekly, …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[346],"class_list":["post-53476","post","type-post","status-publish","format-standard","hentry","category-conference-reports","tag-croi-2026"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/53476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=53476"}],"version-history":[{"count":9,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/53476\/revisions"}],"predecessor-version":[{"id":53753,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/53476\/revisions\/53753"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=53476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=53476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=53476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\nShort review of exciting results and potential cautions with new ART combinations.<\/li>\n
\n<\/a>Update on rare cases of breakthrough HIV infection using lenacapavir PrEP.<\/li>\n
\nThe second stage of RIO study compared viral dynamics after a second course of bNAbs when viral load took longer to rebound and to lower peak levels after a second course of treatment.<\/li>\n
\nGLP-1 studies of weight loss drugs included short-term impact in a real world setting, potential benefits on reducing smoking, cardiovascular risk, depression, and liver fibrosis with the oral abstract on the potential to perhaps reverse the gut damage that occurs in very early HIV infection and that persists despite effective ART. Still lots of gaps in data though.<\/li>\n
\nA new once-daily pill can effectively simplify ART for many on complicated combinations. This is a tiny pill – smaller than Biktarvy – and let many people stop boosted PIs – or other complex combinations used by older people who have been on ART for more than 20 years.<\/li>\n
\nShort review of a plenary talk by John Mellors on the latest understanding about the HIV latent reservoir. Also highlights the RIO study.<\/li>\n
\nLatest developments and approaches to long-acting and extended formulations from independent investigators and research companies at the important annual pre-CROI meeting.<\/li>\n<\/ul>\n\n
\nThis new study is the second randomised clinical trial to report no benefit against gonorrhoea for gay men given the 4CMenB vaccine. Many questions for why these results are so different to observational studies and generated a lot of discussions and questions.<\/li>\n
\nThis phase 3 study showed that a new oral drug called pritelivir can work in people who have drug resistance to other herpes treatments. Available now in an expanded access programme while being reviewed by the FDA.<\/li>\n
\nLong-term results from this 8-year French PrEP study in predominantly gay men continued to show efficacy of 2:1:1 dosing and the flexibility to switch to daily dosing and back depending on your circumstances.<\/li>\n
\nAnalysis of the impact of last year’s US policies \u2013 and inspiring strategies for how to overcome them this year. The talk drew on the unique and dynamic history of ACT-UP to give us strength and hope for the future, when the current US administration will be replaced.<\/li>\n
\nThe study looking as dose selection for this very exciting option for once-monthly oral PrEP.<\/li>\n
\nAn interesting study by independent investigators looking at this now discontinued PrEP drug against HIV with drug resistance. Luckily, this is unlikely to affect the new replacement compound MK-8527.<\/li>\n
\nA statement by the conference organiser’s reflects the concerns of researchers to the current anti-science policies of the Trump administration. It is shocking that organises needed to do this but very important that they did.<\/li>\n
\nAn early overview covering new HIV drugs, new PrEP drugs, bNAbs, HIV complications, GLP-1 weight-busting drugs in people with HIV, cure-related research, key populations, \u00a0the impact of US policy changes, new monitoring testa and more.<\/li>\n<\/ul>\n